Payment overview · 2025
General Payments
$46.05
3 reported records · 3 companies
Healthcare provider profile · identity verified
David Christopher Murphy, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SNOWFLAKE, AZ · NPI 1417480047
Verified facts
What the public records show
CMS Open Payments records show David Christopher Murphy, D.O. received $46.05 in general payments during 2025 across 3 reported records.
Merck Sharp & Dohme LLC accounted for 35.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.32 | 35.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.89 | 34.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.84 | 30.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $46.05 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 439 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 363 | 114 |
| Omeprazole | Omeprazole | 268 | 79 |
| Losartan Potassium | Losartan Potassium | 258 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 67 |
| Gabapentin | Gabapentin | 220 | 50 |
| Metformin Hcl | Metformin Hcl | 219 | 72 |
| Meloxicam | Meloxicam | 157 | 40 |
| Ozempic | Semaglutide | 157 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 55 |
| Tramadol Hcl | Tramadol Hcl | 141 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 44 |
| Furosemide | Furosemide | 124 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 124 | 31 |
| Doxepin Hcl | Doxepin Hcl | 123 | 24 |
| Eliquis | Apixaban | 120 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 31 |
| Pregabalin | Pregabalin | 93 | 19 |
| Trazodone Hcl | Trazodone Hcl | 85 | 29 |
| Carvedilol | Carvedilol | 82 | 20 |
| Simvastatin | Simvastatin | 76 | 24 |
| Trulicity | Dulaglutide | 76 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 25 |
| Potassium Chloride | Potassium Chloride | 72 | 21 |
| Alendronate Sodium | Alendronate Sodium | 71 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 25 |
| Sertraline Hcl | Sertraline Hcl | 68 | 22 |
| Jardiance | Empagliflozin | 64 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 15 |
| Alprazolam | Alprazolam | 61 | 21 |
| Propranolol Hcl | Propranolol Hcl | 61 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 31 |
| Buspirone Hcl | Buspirone Hcl | 59 | 18 |
| Montelukast Sodium | Montelukast Sodium | 57 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 18 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 55 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 14 |
| Lorazepam | Lorazepam | 52 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 12 |
| Atenolol | Atenolol | 48 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 13 |
| Warfarin Sodium | Warfarin Sodium | 47 | 11 |
| Chlorthalidone | Chlorthalidone | 39 | 13 |
| Estradiol | Estradiol | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Famotidine | Famotidine | 38 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 14 |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Finasteride | Finasteride | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Prednisone | Prednisone | 34 | 25 |
| Diazepam | Diazepam | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | 12 |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | 11 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | 11 |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Junel | Norethindrone Ac/Eth Estradiol | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $46.05 · 3 records | Merck Sharp & Dohme LLC | BEXSERO, CAPVAXIVE, Cologuard Collection Kit, ENFLONSIA, GARDASIL 9, PEDIARIX, ROTATEQ, SHINGRIX, VAXNEUVANCE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error